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Kinetics of the inhibition of human factor Xa by full-length and truncated
recombinant tissue factor pathway inhibitor
Theo LINDHOUT,* George WILLEMS, Ron BLEZER and H. Coenraad HEMKER
Department of Biochemistry, Cardiovascular Research Institute Maastricht, University of Limburg, P.O. Box 616, 6200 MD Maastricht, The Netherlands
The inhibition equilibrium and kinetics of association and
dissociation of the binding of three types of recombinant tissue
factor pathway inhibitor (TFPI), namely full-length TFPI, C-
terminal-truncated TFPI, and TFPI without the third Kunitz
domain (TFPI1 1161) to factor Xa have been measured. Formation
and dissociation of the complexes were monitored by continuous
measurement of the changes in the rate of hydrolysis of a
peptidyl-p-nitroanilide substrate. Progress curves of product
formation were fitted to a set of equations describing a one-step
bimolecular inhibitory reaction in the presence of a competing
substrate. For full-length TFPI the rate constants of association
INTRODUCTION
The enzymic machinery involved in the blood-coagulation pro-
cess is controlled by a number of positive- and negative-feedback
systems. As a result, blood coagulation is a system that, on the
one hand, responds rapidly to small triggering signals and, on the
other hand, is rapidly shut down so that it does not propagate
beyond the site of injury. The key steps in the regulation of this
process are the activation and inactivation of membrane-bound
proteins which function as essential cofactors of membrane-
bound enzymes, e.g. activation of factors V and VIII by thrombin
and their inactivation by activated protein C (for a review see
[1]).
The enzymic complex that consists of the cofactor tissue factor
(TF, an integral membrane glycoprotein) and the serine protease
factor Vlla is thought to be the major initiator of the blood-
coagulation process in vivo [2]. The neutralization of the enzymic
activity of this complex by tissue factor pathway inhibitor (TFPI),
a 42 kDa glycoprotein consisting of three tandem Kunitz-type
inhibitor domains, a negatively charged N-terminus and a
positively charged C-terminus [3], is assumed to cause an essential
shift in the coagulation pathways [4-6]. That is, an initial burst
of TF-factor VIla-dependent factor Xa generation is turned off
by TFPI, and is then followed by a maintenance dose of factor
Xa produced by the classic 'intrinsic' pathway. Factor Xa seems
to play an essential role in shutting off its own generation [7-9],
because the inhibition of the TF/VIIa activity by plasma
concentrations of TFPI is only significant when factor Xa is also
present. The final product of the inhibition reaction is a dis-
sociable quaternary Xa/TFPI/VIIa/TF complex [5].
In order to understand the importance of this regulatory
process and the potential therapeutic role of TFPI as an
anticoagulant drug, knowledge of the kinetics of the formation
of the quaternary complex is essential. It emerged from studies
reported so far that the ability of TFPI to inhibit TF/VIIa-
induced coagulation seems to depend on the rate of association
(k.n) and dissociation (kIc,) were (5.1 +0.7) x 106 M-1 s-. and
(2.6 + 0.9) x 10-4 s-I respectively. Thus, although the inhibition
constant (50 pM) is far below the plasma concentration (2.5 nM)
of TFPI, the half-time for transition to equilibrium in plasma is
rather long (66 s). The truncated forms of TFPI differ in that
they have a 4-fold lower kon value but a similar dissociation rate
constant. Therefore the inhibition constant, K1, is 4-fold higher
(0.2 nM) and the half-time to achieve equilibrium is prolonged to
250 s. The kon values of full-length and C-terminal-truncated
TFPI, but not that of TFPI1161, were found to decrease with
increasing ionic strength.
between factor Xa and TFPI, the first step in the formation
of the inactive Xa/TFPI/VIIa/TF complex [10,11]. It has been
postulated that TFPI is a slow, tight-binding, competitive and
reversible inhibitor of factor Xa [5], but so far no data have been
reported on the association and dissociation rate constants. In
this paper we report on the rates of association and dissociation
of complex-formation between human factor Xa and TFPI. We
have examined three variants of recombinant TFPI, namely full-
length TFPI, the C-terminal truncated TFPI lacking the highly
basic sequence of residues 254-265, and TFPI truncated between
the second and third Kunitz domains (TFPI1 161). The role of the
basic C-terminus in the interaction between factor Xa and TFPI
was also examined by varying the ionic strength.
EXPERIMENTAL
Materials
The chromogenic substrate for factor Xa, methoxycarbonyl-D-
cyclohexylglycyl-glycyl-arginine p-nitroanilide (Spectrozyme
FXa) was from Pentapharm (Basel, Switzerland). BSA (fatty-
acid-free) was purchased from Sigma (St. Louis, Mo, U.S.A.).
All reactions were carried out at 37 °C in 50 mM Tris/HCl,
containing 175 mM NaCl and 0.5 mg of BSA/ml, pH 7.9
(TBSA).
Proteins
The human coagulation factor Xa was purified to homogeneity
and quantified as previously described [12]. The recombinant
TFPI preparations were kindly supplied by Dr. Ole Nordfang
(Novo Nordisk, Gentofte, Denmark). Full-length recombinant
human TFPI (FL-TFPI) and the C-terminal-truncated variant of
TFPI lacking the C-terminal basic region were obtained from
transfected baby-hamster kidney cells as described previously
[13] and were separated by cation-exchange chromatography
[10]. The preparation of truncated TFPI consisted of a mixture
Abbreviations used: TF, tissue factor; TFPI, tissue factor pathway inhibitor; TFPI1-161, recombinant C-terminal-truncated TFPI containing residues
1-161; TBSA, 50 mM Tris/HCI (pH 7.9) containing 175 mM NaCI and 0.5 mg of BSA/ml; pNA, p-nitroanilide.
* To whom correspondence should be addressed.
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of variants ending at amino acids Ile-247, Ser-248, Gly-250 and
Thr-255 [10]. The C-terminal-truncated variant of TFPI lacking
the third Kunitz-type domain and the C-terminal region
(TFPII1,61) was expressed in Saccharomyces cerevisiae and
purified as described previously [14]. All preparations of TFPI
were more than 95o% pure, as judged from Coomassie-Blue-
staining after SDS/PAGE.
Factor Xa assay
The assay was performed in polystyrene cuvettes at 37 °C in
0.5 ml of TBSA containing 300,M Spectrozyme FXa. Hy-
drolysis of the peptidyl p-nitroanilide substrate was initiated by
addition of factor Xa. The A405 was monitored and the amount
of product formed was calculated by using an absorption
coefficient of 9900 M-l cm-'. The Km and k,a, values of the
reaction were estimated from initial-rate measurements at
different substrate concentrations, and were 310 ,uM and 250 s-
respectively.
Determinations of the TFPI molar concentratlons
TFPI (10 nM) was incubated in 470 ,ul of TBSA with increasing
amounts of factor Xa. After 30 min at 37 °C, 30 1l of 5 mM
Spectrozyme FXa was added and the residual amount of factor
Xa was calculated from its known specific activity towards
Spectrozyme FXa. The linear part of the titration curve was
extrapolated, and the intercept with the axis representing the
total factor Xa concentration was taken as the molar con-
centration of TFPI in the reaction mixture. It was assumed that
factor Xa forms an equimolar complex with TFPI.
Measurement of K,
Factor Xa was titrated with increasing amounts of TFPI
(0-10 nM) in a cuvette with 470 ,ul ofTBSA for 40 min at 37 'C.
The residual factor Xa activity was determined from the initial
rate of p-nitroanilide (pNA) production as described. A series of
three such titrations were done for each form of TFPI:
0.75-1.5-3.0 nM factor Xa for TFPI 1161' 0.2-0.4-0.8 nM factor
Xa for C-terminal-truncated TFPI, and 0.1-0.2-0.5 nM
factor Xa for full-length TFPI. The data were expressed as the
ratio of inhibited velocities (vs) to the control velocity in the
absence of TFPI (vo).
Progress curves
Progress curves of pNA production in the presence of factor Xa
(0.4 nM) and varying amounts of the different forms of TFPI
were conducted in cuvettes at 37 'C in 0.5 ml of TBSA. The
hydrolysis of the peptidyl substrate by factor Xa was monitored
at 405 nm during 2 min. Then a small sample (1-20 ,ul) of TFPI
was added. The reaction was monitored until factor Xa, TFPI
and substrate attained a steady-state equilibrium. Data sampling
was performed every 1 s. Progress curves were also obtained by
preincubation of factor Xa with different concentrations ofTFPI
for at least 40 min at 37 'C and starting the reaction by the
addition of a portion (50 ,ll) of the reaction mixture to a cuvette
with 450 ,ul of TBSA containing 300 ,uM Spectrozyme FXa.
Theory and data analysis
The inhibition of factor Xa (E) by TFPI (I) in the presence of a
peptidyl pNA substrate (S) is analysed by using the simplest
scheme for competitive inhibition (Scheme 1):
E+ S ES kca P
+
I
kon t; koff
El
Scheme 1
It was further assumed that the steady-state equilibrium between
factor Xa and the substrate was attained instantaneously.
Equilibrium studies
The inhibitor constant K, can be calculated from
vl/vo = ([E]0 - ['] -K, + V/{([E]o + [I]o+ Ki)'
-4[E]o[1]0})/2[E]o (1)
where v./vo is the ratio of inhibited velocity to the control
velocity in the absence of inhibitor and [E]o and [I]o are the
enzyme and inhibitor concentration respectively [15,16]. The
observed v./vo values of a set of three TFPI titration curves at
different fixed amounts of factor Xa were fitted simultaneously
by a non-linear least-squares regression algorithm (BMDP Stat-
istical Software Inc., Los Angeles, CA, U.S.A.) to eqn. [1] to
obtain an estimate of the inhibitor constant K1.
Progress curves
Data from progress curves ofpNA production in the presence of
TFPI were fitted by the non-linear least-squares regression
algorithm to the following coupled system of differential
equations:
d(P)/dt = kcat ([E]o- [El]) {([S]O - [P])/(Km + [S]O - [P])}(2)
d(EI)/dt = k aPP ([E]o-[El]) ([I]O-[EI])-koff[EI] (3)
where
konaPp = kon Km/(S +Km)
with addition of TFPI to the factor Xa-substrate mixture at zero
time. Thus the initial conditions are: [P]0 = 0 and [EI]o = 0.
Data from progress curves in the absence of TFPI were fitted
to the following equation:
d(P)/dt = kcat [E]o(l -e-ekt) {([S]O- [P])/(Km + [S]0- [P])}
(4)
Since no inhibitor of factor Xa was added, the pseudo-first-order
rate constant k reflects non-specific loss of factor Xa activity.
When preincubated mixtures of factor Xa and TFPI were
added to a solution containing the substrate for factor Xa, the
initial concentration of the factor Xa-TFPI complex (El) in the
cuvette is given by eqn. (5):
[El]o = ([E]o + [']o + Ki/d- V{([E]o + [I]o + Ki/d)2
-4[E]o[I]oj)/2 (5)
where [E]o and [I]o are the total concentrations of factor Xa and
TFPI in the cuvette and d is the ratio of the final volume of the
reaction mixture to the sample volume of the preincubation
mixture. The progress curves were fitted to the system of coupled
differential equations (2) and (3), with the boundary conditions
given by equation (5) and [P]0 = 0. The estimated parameters
were ko app. and k The value for kcat was held constant at the
independently determined value of 250 s-'.
RESULTS
Inhibition kinetics as derived from progress curves stated with
factor Xa
The kinetics of factor Xa-TFPI complex-formation were derived
from progress curves of factor Xa-catalysed pNA formation in
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Figure 1 Time course of inhibition of human factor Xa by full-length TFPI
Spectrophotometer tracings showing hydrolysis of peptidyl-pNA substrate (300 /uM) by human
factor Xa (0.4 nM) in the absence (a) or presence (b) of full-length TFPI (0.4 nM). Lines a'
and b' are the results of the fitting procedures as described in the Experimental section.
the presence of TFPI. The factor Xa concentrations and those of
the recombinant TFPI variants used in these experiments were
chosen such that the progress curves of product formation
revealed both the progress of inhibition and the steady-state
velocity. Consequently, the TFPI concentration had to be chosen
rather close to the factor Xa concentration, causing a significant
depletion of free TFPI during the course of the reaction. The
rather long duration of the experiments also caused in some cases
a significant depletion of substrate. In our analysis, however, we
corrected for both the depletion of substrate and free inhibitor
(see the Experimental section; cf. eqns. 2 and 3, respectively).
These equations cannot be solved in closed form, and therefore
a numerical solution was used to analyse the experimental data.
A representative example of a plot of pNA versus time for the
factor Xa-catalysed reaction in the absence of TFPI (curve a) is
shown in Figure 1. The simulated curve a', obtained by fitting
eqns. (2) and (3) to the experimental data, is superimposed on the
experimental curve. The residuals, calculated as observed amount
of product minus the predicted value, varied around zero and
were less than 0.05 uM. The estimated kcat and k values were
240 s- and 0.005 min-1 respectively. This value of kcat as
estimated from the progress curve is very close to the value
(250 s-1) determined from initial-rate experiments. The half-life
time of the factor Xa activity is 0.693/0.005 = 150 min, i.e. about
6 times the duration of the experiment. We conclude that the
progress curves in the absence of TFPI are adequately described
by the model. Thus, factor Xa activity was found to be sufficiently
stable, and no signs of product inhibition were observed.
Figure 1 also shows a typical example of a progress curve in
the presence of 0.4 nM full-length TFPI (curve b). The simulated
curve b', obtained by fitting the experimental data to eqns. (2)
and (3), is superimposed on the experimental curve. Again, the
residuals of the observed minus simulated data were very small
(less than 0.02,M) and varying around zero. The standard
errors of the estimated rate constant of association (kon), the rate
constant of dissociation (koff) and the catalytic rate constant of
the factor Xa-substrate reaction (kcat.) were less than 0.1 % of
the value. Thus the progress curves in the presence of TFPI are
also adequately described by the model.
We next verified our assumption that the peptidyl substrate
competes with TFPI for the active site of factor Xa. Progress
curves were performed in the presence of a variety of substrate
concentrations (100-900 /LM). The reactions were started by the
addition of factor Xa (0.25 nM), and after 2 min C-terminal-
truncated TFPI (1 nM) was added. The progress curves in the
presence of TFPI were fitted to eqns. (2) and (3). Figure 2 shows
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2.0
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Figure 2 Effect of factor Xa substrate concentration on kW and ko,
Progress curves of the hydrolysis of peptidyl-pNA substrate (100-900 ,sM) by factor Xa
(0.4 nM) in the presence of C-terminal-truncated TFPI (1 nM) were analysed as described in
the Experimental section to yield apparent kon (0) and apparent kof (0) values.
a replot of the estimated parameters, apparent kon and apparent
k,f, versus Km/(Km+ S). It is apparent that ko,, does not vary
with the substrate concentration, whereas the apparent kon value
is a linear function of Km/(Km + S). Extrapolation to zero
substrate concentration gives a true kon of 2.1 x 106 M-1 * s-5. The
mean+ S.D. of the estimated kcat values was 241 + 8 s-'. This
value closely agreed with the experimental value (250 s-1) as
determined from the rates of pNA production at the different
substrate concentrations in the absence of TFPI. These data
show that the peptidyl substrate indeed competes with TFPI for
the active site. The true kon values can be calculated from the
observed ones by application of the expression
kon =k00aPP (1 +S/Km)
Progress curves were then performed in the presence of varying
amounts of the three different forms of recombinant TFPI. The
kon values corrected for substrate competition and the koff values
as obtained by the fit procedure are listed together with their
standard errors in Table 1. The second-order rate constant
of association of the reaction between full-length TFPI
and factor Xa [(5.08 + 0.68) x 106 M-1 s-'] is about 4-fold
higher than the rate constant found for the reactions of
factor Xa with C-terminal-truncated TFPI and TFP11161
[(1.46+ 0.08) x 106 M-1 * s-' and (1.14+0.15) x 106 M-1 * s-'
respectively]. The rate constant ofdissociation ofthe TFPI-factor
Xa complex was found to be the same for all forms ofrecombinant
TFPI tested [(0.26 + 0.05) x 10-3 s-1]. Progress-curve analysis at a
variety of TFPI concentrations yielded similar kcat values very
close to the experimentally determined value of 250 s-1 (Table 1).
The excellent agreement between model (Scheme 1) and ex-
perimental data suggest that the inhibitory reaction of factor Xa
with TFPI indeed can be described as a simple bimolecular
reaction. However, we have to emphasize that the conditions
under which these observations were made might not discriminate
between a slow bimolecular reaction and a rapid association to
form the E I complex, followed by a slow unimolecular change
to a stable and inactive complex [17].
Inhibition kinetics derived from progress curves started with the
peptidyl substrate
To verify the reversibility of the binding of TFPI to factor Xa,
rate constants were also derived from progress curves of product
formation that were started with the peptidyl substrate. Factor
Xa and TFPI were preincubated at concentrations 10 times those
used in the progress curves started with factor Xa. Recovery of
the factor Xa activity was then continuously monitored after a
*0
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Table 1 KinetIc and equilibrium constants for TFPI-factor Xa complex formation from progress curves stred with factor Xa
Details of the procedures by which the constants were measured are given in the text.
10-1 X kon 103 X koXf 109XK*
Inhibitor Concn. (nM) k>, (s1) (M' .s-) (s1) (M)
Full-length TFPI
Truncated TFPI
0.2
0.4
0.6
0.5
1.0
1.5
0.5
1.0
2.0
238.2 + 0.1
232.4+ 0.1
215.0 + 0.2
238.3 + 0.1
248.0 + 0.2
247.5 + 0.2
247.6 + 0.3
248.1 +0.3
247.3 + 0.5
5.51 + 0.03
4.33 + 0.04
5.40 + 0.02
1.53 + 0.01
1.49+ 0.01
1.37 + 0.01
1.32 + 0.01
1.09 + 0.01
1.02 + 0.01
0.141 + 0.018
0.298 + 0.003
0.300+ 0.001
0.283 + 0.001
0.275 + 0.001
0.271 + 0.001
0.265 + 0.005
0.216 + 0.003
0.320 + 0.003
0.026
0.068
0.056
0.18
0.18
0.19
0.20
0.20
0.32
* Calculated from kol1k,,.
8
(6
._
' 4
02
6,
10 20 30
Time (min)
40 50
Figure 3 Progress curve of the recovery of factor Xa activity
Spectrophotometer tracings showing hydrolysis of peptidyl-pNA substrate (300 ,uM) after
addition of a sample of human factor Xa (4 nM) incubated for 40 min in the absence (a) and
presence (b) of full-length TFPI (4 nM). The final concentrations in the cuvette were 0.4 nM
factor Xa and 0.4 nM TFPI. Line (b') is the result of the fitting procedure as described in the
Experimental section,
10-fold dilution of the preincubated mixture into a cuvette
containing the peptidyl substrate. A typical example of a progress
curve of the recovery of factor Xa activity is shown in Figure 3.
The data from the progress curves were fitted to the differential
equations (2) and (3) with the initial amount of TFPI-factor Xa
complex given by equation (5). The kcat value was held constant
at 250 s-'. The predicted data were in excellent agreement
with the experimental data.-The values of kon and koff as derived
from the fitting procedure are listed together with their standard
errors in Table 2, and are in good agreement with the estimates
given in Table 1.
Determination of the inhibitor constant
The inhibitor constants (K1) of the reactions of factor Xa with the
different forms of recombinant TFPI were determined under
equilibrium conditions in the absence of substrate. K, values were
estimated with different fixed factor Xa concentrations and
varying TFPI concentrations as described in the Experimental
section. The fitting procedure resulted in inhibitor constants of
0.036 + 0.004 nM, 0.311 + 0.009 nM and 0.42+ 0.03 nM for the
full-length TFPI, C-terminal-truncated TFPI and TFP11161 re-
spectively. We note that an equilibrium between factor Xa and
TFPI was established before addition of the substrate. Prolonged
incubation times (60 min) resulted in identical residual factor Xa
activities. Because the residual factor Xa activity was determined
within 1 min after the addition of substrate, and in view of the
slow dissociation of the TFPI-factor Xa complex (2 x 10-4 s-1),
it is assumed that these Ki values represent the true inhibitor
constant. We further note a good agreement between these
experimentally determined inhibitor constants and those
calculated from the rate constants koff and true kon (Tables 1 and
2). This agreement between kinetic and equilibrium data again
Table 2 Kinetic and equilibrium constants for TFPI-factor Xa complex formation from progress curves started with substrate
1 0-6 X ko, 103X k 109x;t
Inhibitor Concn.* (nM) (M-1 s-1) (s 1) (M)
Full-length TFPI
Truncated TFPI
0.2
0.4
0.6
0.5
1.0
1.5
0.5
1.0
2.0
4.19 + 0.03
4.83 + 0.02
6.53 + 0.01
0.987 + 0.002
1.43 + 0.01
1.59 + 0.01
1.110+0.003
0.912 + 0.005
0.51 +0.06
0.167 + 0.001
0.373 + 0.001
0.335 + 0.003
0.181 + 0.003
0.275 + 0.001
0.325 + 0.013
0.283 + 0.001
0.263 + 0.007
0.206 + 0.001
0.039
0.077
0.051
0.18
0.19
0.20
0.25
0.29
0.40
* Final concentration in the assay.
t Calculated from ko,,.ko.
a bl
i i i
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Figure 4 Effect of Ionic strength on k, and k., of the TFPI-factor Xa
reaction
The k,n values (a) and kof values (b) were obtained from progress curves of the hydrolysis of
peptidyl-pNA substrate (300 1sM) by factor Xa (0.4 nM) in the presence of 1 nM TFP11161
(A), 1 nM C-terminal-truncated TFPI (0) and 0.4 nM full-length TFPI (0).
reinforces our conclusion that the simplified model allows an
adequate description of the experimental data.
Effect of ionic strength on the factor Xa-TFPI inhibitory reaction
Among the three different forms of TFPI, the full-length TFPI
showed the highest kon and lowest K1 value in the interaction with
human factor Xa. Since only the full-length TFPI contains a
highly positively charged C-terminus, it was expected that elec-
trostatic interactions between factor Xa and TFPI determines to
some extent the binding kinetics. We therefore examined the
effect of ionic strength (I) of the reaction medium on the kinetic
constants, kon and KM of the reaction of factor Xa with the three
recombinant forms of TFPI.
We first determined at each ionic strength the kcat and Km
values of the reaction between factor Xa and the peptidyl
substrate Spectrozyme FXa. We found that the Km varied from
150 prM at I = 0.1 to 400 ,tM at I = 0.4. The I had no effect on
the kcat* Progress curves in the presence of a fixed amount of
TFPI were then performed in TBSA buffer containing varying
amounts of NaCl. The value of Km as determined at each I value
was held fixed at this value for the analysis of the progress-curve
data according to eqns. (2) and (3). Figure 4 shows the effect of
I on the kinetic constants of the reactions between factor Xa and
full-length TFPI, C-terminal-truncated TFPI and TFPI, 161. The
kon values were corrected for substrate competition by application
of the expression k1n = k0 aPP (1 + S/Km). The standard errors of
the estimates were less than 1 % of the value. It is apparent that
I hardly affected the binding kinetics of TFPIl-161 to human
factor Xa. Interestingly, the C-terminal-truncated TFPI showed
the strongest dependency on I in its reaction with factor Xa.
Moreover, the differences between truncated TFPI and full-
length TFPI with respect to their kon values almost disappeared
at low I.
DISCUSSION
The much higher anticoagulant activity of full-length TFPI, as
compared with a C-terminal-truncated TFPI, is attributed to a
C-terminal-mediated inhibitory activity of the full-length TFPI
against factor Xa [10,1 1]. However, no differences were detected
between the two forms of TFPI in the initial rates of tissue
factor/factor Vlla-catalysed factor X activation in a buffer
system [11]. To understand the structure-function relationships,
it thus becomes increasingly important to derive the kinetic
constants of the factor Xa-TFPI reaction on the basis of an
appropriate kinetic model of that interaction.
We based our kinetic model on the assumption that the
association process between factor Xa and the different
recombinant forms of TFPI is a reversible bimolecular reaction
(Scheme 1). It is very likely that we over-simplified the mechanism
of action of the inhibitor. Laskowski and Kato [18] proposed a
standard mechanism of action of Kunitz-type inhibitors in which
the stable protease-inhibitor complex is preceded by a loose pre-
equilibrium complex. Consequently, in the latter case the
estimated kinetic constants obtained with the model as depicted
in Scheme 1 describe the overall process of inhibition, including
all steps before equilibrium is attained.
Three different approaches were used to generate the data
from which the association rate constants (kon) and disssociation
rate constants (koff) as well as the inhibition constant, K1, were
obtained: (1) the formation of the inactive factor Xa-TFPI
complex was monitored by continuous measurement of the
changes in the rate of pNA formation, (2) the rate of pNA
formation was continuously monitored after preincubating factor
Xa with TFPI in the absence of substrate and diluting the
factor Xa-TFPI complex into a reaction mixture containing the
peptidyl substrate, and (3) the residual factor Xa activity
after preincubating factor Xa and TFPI was measured from the
initial rate of pNA formation after the addition of peptidyl
substrate to the reaction mixture.
The present data show that the different experimental settings
yielded virtually identical values for the rate constants kon and
koff (Tables 1 and 2). In addition, the K1 values calculated from
the rate constants were comparable with those determined from
equilibrium experiments. The data thus strongly indicated that
the kinetics of the TFPI-factor Xa reaction could be adequately
described by Scheme 1. Our observation that the estimated kcat
value did not vary significantly with the TFPI concentration
(Tables 1 and 2) is also consistent with a mechanism of inhibition
in which factor Xa and TFPI slowly interact. However, it should
be pointed out that these observations did not exclude a two-step
mechanism. We wish to emphasize that the time-dependence
of the reaction between factor Xa and the TFPI variants was
such that at TFPI concentrations higher than 1 nM for full-
length TFPI, and higher than 2 nM for C-terminal-truncated
TFPI and TFP11161, the duration of pre-steady state became too
short to be analysed. Thus we were unable to vary the TFPI
concentration over a sufficiently wide range to ensure that a
kinetically relevant concentration of an initial weakly associated
intermediate TFPI-factorXa complex was not generated. Indeed,
a numerical simulation of the two-stage model revealed that for
TFPI concentrations that are 10-20% of the dissociation
constant of the rapidly dissociable intermediate TFPI-factor Xa
complex, and for association rates exceeding 4-5 times the
observed rate, the kinetics of the one- and two-stage models
are indistinguishable (results not shown). At higher TFPI
concentrations the simulations predicted a discrepancy between
the values of the inhibitor constant obtained from equilibrium
experiments and those estimated from the progress curves.
The model, as depicted in Scheme 1, predicts that the peptidyl
substrate for factor Xa competes with the binding ofTFPI to the
active site of factor Xa. Indeed, the association rate constant
is a linear function of Km/(Km+ 5). As was expected for a
reversible binding interaction, the dissociation rate constant did
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Table 3 KInetic constants (mean+ S.D.) and halt-time for transition to
equilibrium
Inhibitor 1 0-6 x k0, (M-1 * s-') 1 04 x kff (S-1) t* (s)
Full-length TFPI 5.13 + 0.87 2.56 + 0.93 66
Truncated TFPI 1.40+ 0.21 2.68 + 0.46 226
TFPI11161 1.08+ 0.14 2.82 + 0.50 283
* Half-time for transition to equilibrium.
not vary with the substrate concentration (Figure 3). However,
the extent of dissociation is affected by a competing substrate;
Ki (app.) increased with substrate concentration.
The average kon and koff values (+ S.D.) of the different forms
of TFPI calculated from the data shown in Tables 1 and 2 are
summarized in Table 3. The rate constant of association of full-
length TFPI is about 4 times the rate constants of association
found for C-terminal-truncated TFPI and TFP11161. Apparently,
the positively charged C-terminal region of TFPI is involved in
the association process with factor Xa, which then points to an
ionic interaction being important in the binding of full-length
TFPI to factor Xa. Our data on the association kinetics as
obtained at different ionic strength, however, suggest that ionic
interaction is also important in the reaction between C-terminal-
truncated TFPI and factor Xa. The binding kinetics of TFPI
lacking the third Kunitz domain (TFP11161) were not sensitive to
variations in ionic strength. The data further suggest that the
differences between the kinetics of full-length TFPI and C-
terminal-truncated TFPI diminish at low ionic strength.
While our investigation was in progress, Wesselschmidt et al.
[11] reported K, values of 3 and 20 pM for factor Xa inhibition
by full-length and C-terminal-truncated TFPI respectively. The
values reported in the present paper were 36 pM and 310 pM
respectively. Thus, despite the similarities in experimental con-
ditions (buffer, concentrations of reactants), our values are more
than 10-fold higher than as reported by Wesselschmidt et al. [11].
Whether differences in experimental design, data analysis and the
types of cells used to express the proteins caused this disparity
remains to be seen. Interestingly, 30-fold greater K, values were
reported by the same group for TFPI produced by HepG2 [5].
If we assume that under physiological conditions the TFPI
concentration in plasma (2 nM) exceeds that of factor Xa and
that competing ligands can be ignored, the half-times for
transition to equilibrium can be estimated from the expression:
ti = 0.693/(ko0[TFPI] + koff)
When the data as presented in Table 3 are put in a physiological
context, it is evident that, of the different variants of TFPI, full-
length TFPI is the better inhibitor of factor Xa. Both its
equilibrium position ([TFPI]/K, = 70) and the time required to
produce half-saturation of factor Xa (66 s) point to a greater
potency than the other forms of TFPI ([TFPI]/K6 = 13 and a
Li of complex-formation of 250 s). In considering the speed of
reaction, the rate of dissociation (reversibility of the complex
formation) can be ignored for full-length TFPI, but also for the
truncated forms: the half-lifetime of the TFPI-factor Xa
complexes is 3500 s.
When compared with other (natural) inhibitors of factor Xa,
such as antithrombin III-heparin, full-length TFPI is a faster-
reacting inhibitor: the bimolecular rate constants are
6.4x 10 M-1 s- [19] and 5.1 x 106M-1M s- (Table 3) respec-
tively. However, when we take into account a 1000-fold
difference in plasma concentration, antithrombin III (even in the
absence of heparin) becomes as important as TFPI as a factor Xa
inhibitor (under the assumption that depletion of TFPI does not
occur). That is, the half-lifetime of factor Xa activity in plasma
is 84 s [20] and that of factor Xa in the presence of 2 nM of the
native full-length TFPI is 66 s (Table 3). Therefore, it may not be
excluded that TFPI, in addition to its specific function in
inhibiting tissue-factor-dependent factor Xa generation, also acts
as a physiologically important inhibitor of factor Xa.
As yet, it remains to be seen whether the kinetic data of the
bimolecular reaction between TFPI and factor Xa reflect the
kinetics of the inhibitory reaction between TFPI and TF/factor
Vlla-catalysed factor Xa generation. If so, then one could
speculate that TFPI is a rather inefficient inhibitor, because, due
to its relative long half-time of complex-formation with factor
Xa (66 s) and the high catalytic efficiency of the initiator of blood
coagulation (TF/factor Vlla), a large amount of factor Xa can
be produced before the activator is neutralized.
We thank Dr. Ole Nordfang (Novo Nordisk, Gentofte, Denmark) for providing the
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